MARKET

NERV

NERV

Minerva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.330
+0.400
+13.65%
After Hours: 3.230 -0.1 -3.00% 18:53 05/17 EDT
OPEN
2.950
PREV CLOSE
2.930
HIGH
3.370
LOW
2.920
VOLUME
2.15M
TURNOVER
--
52 WEEK HIGH
15.22
52 WEEK LOW
1.810
MARKET CAP
142.26M
P/E (TTM)
57.51
1D
5D
1M
3M
1Y
5Y
Do Options Traders Know Something About Minerva Neurosciences (NERV) Stock We Don't?
Zacks.com · 11h ago
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
Zacks · 4d ago
62 Biggest Movers From Yesterday
Gainers
Benzinga · 4d ago
Why Minerva Neurosciences' Stock Is Trading Higher Today
Minerva Neurosciences (NASDAQ:NERV) shares are trading higher after the company announced results from the 40-week open-label extension of its phase 3 trial of roluperidone for the treatment of negative symptoms of schizophrenia.
Benzinga · 5d ago
Biotech Stock Roundup: REGN's Q1 Earnings Update, MRNA's Vaccine Data & More
The biotech sector was in focus last week with earnings updates from Regeneron (REGN) and Moderna (MRNA) and regulatory updates from Amgen, among others.
Zacks · 5d ago
CRIS, EYES, LMND and CURI among midday movers
Gainers: Curis (CRIS) +53%.Second Sight Medical Products (EYES) +44%.Summit Wireless Technologies (WISA) +39%.Barnwell Industries (BRN) +36%.Autolus Therapeutics (AUTL) +31%.Ra Medical Systems (RMED) +29%.ShotSpotter (SSTI) +23%.Ideal Power (IPWR) +22%.Min...
Seekingalpha · 5d ago
Minerva Neurosciences Shares Up 25% After Co. Reports on Roluperidone Trial
By Stephen Nakrosis Minerva Neurosciences Inc. shares soared in midday trading Wednesday after the biopharmaceutical company posted results from a phase 3...
marketwatch.com · 5d ago
Ra Medical Systems, Nemaura Medical leads healthcare gainers; InflaRx, Praxis Precision Medicines among major losers
Gainers: Ra Medical Systems (RMED) +67%, Nemaura Medical (NMRD) +23%, Lucira Health (LHDX) +21%, Minerva Neurosciences (NERV) +20%, Harrow Health (HROW) +19%.Losers: InflaRx (IFRX) -15%, Praxis Precision Medicines (PRAX) -14%, Lianluo Smart (LLIT) -14%, Re...
Seekingalpha · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NERV. Analyze the recent business situations of Minerva through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NERV stock price target is 7.00 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 136
Institutional Holdings: 43.11M
% Owned: 100.91%
Shares Outstanding: 42.72M
TypeInstitutionsShares
Increased
15
1.50M
New
3
197.29K
Decreased
13
452.36K
Sold Out
4
155.52K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Remy Luthringer
Chief Financial Officer/Executive Vice President
Geoffrey Race
Chief Operating Officer/Senior Vice President
Joseph Reilly
Senior Vice President/Chief Accounting Officer
Frederick Ahlholm
Senior Vice President/General Counsel
Devin Smith
Senior Vice President
Jay Saoud
Other
Michael Davidson
Lead Director/Independent Director
William Doyle
Independent Director
Hans Hasler
Independent Director
Jeryl Hilleman
Independent Director
G. van Heek
Independent Director
David Kupfer
Independent Director
Fouzia Laghrissi-Thode
Independent Director
Jan van Heek
No Data
  • All
  • Financials
  • Insiders
More
About NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

Webull offers kinds of Minerva Neurosciences Inc stock information, including NASDAQ:NERV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NERV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NERV stock methods without spending real money on the virtual paper trading platform.